Holen Sie sich die Stockscreener-App
25.89
1.56%
-0.41
Vorhandelsmarkt:
27.38
1.49
+5.76%
Schlusskurs vom Vortag:
$26.30
Offen:
$26.3
24-Stunden-Volumen:
135.23K
Relative Volume:
2.47
Marktkapitalisierung:
$1.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-7.77%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$25.20
$27.04
1-Wochen-Bereich:
$24.21
$27.94
52-Wochen-Spanne:
$23.00
$32.00
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Firmenname
Hemab Therapeutics Holdings Inc
Sektor
Branche
Telefon
45 2138 7627
Adresse
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
25.89 | 1.23B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com Australia
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga España
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
Hemab Therapeutics Holdings (COAG) Stock Forecast & Analyst Ratings - Moomoo
Hemab Therapeutics Holdings Inc. (COAG) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Hemab, Seaport surge as clinical-stage biotechs make trading debuts - MSN
AI DEN-MAB LLC discloses 4,876,344 Hemab Therapeutics (COAG) shares - Stock Titan
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Closes Upsized Initial Public Offering on Nasdaq - Global Legal Chronicle
RA Capital reveals 16.6% stake in Hemab Therapeutics (NASDAQ: COAG) - Stock Titan
RA Capital funds boost Hemab Therapeutics (COAG) stake with open-market buys - Stock Titan
Hemab Therapeutics (COAG) Insider Trading Activity 2026 - MarketBeat
Access Industries (NASDAQ: COAG) discloses 10.4% Hemab Therapeutics ownership stake - Stock Titan
Board member Laura Tadvalkar resigns from Hemab Therapeutics (NASDAQ: COAG) board - Stock Titan
Hemab Therapeutics Holdings, Inc. Announces Resignation of Laura Tadvalkar as Member of the Board of Directors , Effective on May 8, 2026 - marketscreener.com
Hemab Therapeutics (COAG) 10K Form and Latest SEC Filings 2026 - MarketBeat
Deep Track (COAG) reports 8.15% ownership in Hemab Therapeutics - Stock Titan
Finanzdaten der Hemab Therapeutics Holdings Inc-Aktie (COAG)
Es liegen keine Finanzdaten für Hemab Therapeutics Holdings Inc (COAG) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):